Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.62 |
| ▸ | ULK1 | O75385 | 1/20 | 0.56 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788050 | 1.00 | SCN3A (0.62) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL15652522 | 0.95 | ULK1 (0.62) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL15652723 | 0.92 | SCN3A (0.52) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL13388756 | 0.87 | SCN3A (0.64) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL7692273 | 0.86 | SCN3A (0.56) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL29365790 | 0.86 | SCN3A (0.56) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL24609551 | 0.84 | SCN3A (0.55) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL13379539 | 0.84 | SCN3A (0.58) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL873241 | 0.84 | SCN3A (0.55) | SCN3ASCN9AULK1PSMB8SCN5A | |
| SCHEMBL1751199 | 0.84 | SCN3A (0.55) | SCN3ASCN9AULK1PSMB8SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7070629-B2 | Dye composition comprising at least one diaminopyrazole oxidation base, at least one paraphenylenediamine oxidation base comprising a cyclic amino group, and at least one coupler | L'OREAL, S.A. (FR) | 2006-07-04 | — | — | US | claimed |
| US-20040231066-A1 | Dyeing composition comprising a diaminopyrazole-type oxidation base, a paraphenylenediamine-type oxidation base with cyclic amino group and a coupling agent | L'OREAL S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1432389-A1 | DYEING COMPOSITION COMPRISING A DIAMINOPYRAZOLE-TYPE OXIDATION BASE, A PARAPHENYLENEDIAMINE-TYPE OXIDATION BASE WITH CYCLIC AMINO GROUP AND A COUPLING AGENT | L'OREAL (FR) | 2004-06-30 | — | — | EP | claimed |
| WO-2003028689-A1 | DYEING COMPOSITION COMPRISING A DIAMINOPYRAZOLE-TYPE OXIDATION BASE, A PARAPHENYLENEDIAMINE-TYPE OXIDATION BASE WITH CYCLIC AMINO GROUP AND A COUPLING AGENT | L'OREAL (FR) | 2003-04-10 | — | — | WO | claimed |
| EP-0937713-B1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | BRISTOL MYERS SQUIBB CO (US) | 2001-10-17 | — | — | EP | claimed |
| JP-11269143-A | — | — | None | — | — | JP | disclosed |
| WO-2018019252-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS FAK/AURORA KINASE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2018-02-01 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2099453-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1937271-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | Bayer HealthCare AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1933841-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1149576-A1 | Oxidative dyeing composition for keratinic fibres comprising 1-(4-aminophenyl)pyrrolidine and a sugar-based polymer | L'OREAL (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149575-A1 | Oxidative dyeing composition for keratin fibres comprising 1-(4-aminophenyl)-pyrrolidine and a particular direct dye | L'OREAL (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149577-A1 | Oxidative dyeing composition for keratinic fibres comprising 1-aminophenyl-pyrroilidine and a cationic polymer | L'OREAL (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-1147763-A1 | Oxidative dyeing composition for keratinic fibres containing 1-(4-aminophenyl)-pyrrolidine and an enzymatic oxidation system | L'OREAL (FR) | 2001-10-24 | — | — | EP | disclosed |
| EP-0937713-B1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | BRISTOL MYERS SQUIBB CO (US) | 2001-10-17 | — | — | EP | disclosed |
| JP-H11269143-A | N-(4-AMINOPHENYL)PROLINEAMIDE, ITS USE AND COMPOSITION CONTAINING THE SAME | BRISTOL MYERS SQUIBB CO | 1999-10-05 | — | — | JP | disclosed |
| EP-0937713-A1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | Bristol-Myers Squibb Company (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5876464-A | AQUEOUS SOLUTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231066-A1 | Dyeing composition comprising a diaminopyrazole-type oxidation base, a paraphenylenediamine-type oxidation base with cyclic amino group and a coupling agent | KRT18, AOC1, DPYD | SCN3A 1334/4885SCN9A 1723/4885ULK1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.